Introduction

The therapeutic landscape of renal cell cancer has evolved rapidly over the past 2 years with nivolumab and ipilimumab for patients with metastatic disease and an intermediate or poor prognosis, in the first line setting. More recently, data from trials combining antiangiogenic agents and immune checkpoint inhibitors demonstrated a major benefit of this treatment approach for all patients.

Areas covered

One of three recent trials evaluated the combination of atezolizumab, an anti-programmed death ligand 1 antibody, with bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody. In this manuscript, we summarize the preclinical, clinical, and safety data on atezolizumab for treatment of renal cell carcinoma and describe ongoing trials.

Expert opinion

Atezolizumab was evaluated in combination with an antiangiogenic agent. These trials were designed based on the hypothesis that selecting patients according to the expression of programmed death ligand 1 would increase the benefit of the treatment combination. Despite positive effects on the primary endpoints progression-free survival and response rate in this selected population, overall survival in the global population did not meet the criteria for significance at the time of the intermediate analysis. The major information was a proposed tumor gene expression signature. The signature was predictive of the sensitivity to anti-angiogenic and/or immune checkpoint inhibitor therapy.

中文翻译：

---

Atezolizumab用于治疗肾细胞癌。

介绍

肾细胞癌的治疗前景在过去两年中迅速发展，在第一线治疗中，对于转移性疾病和中度或不良预后的患者，使用nivolumab和ipilimumab治疗。最近，结合抗血管生成剂和免疫检查点抑制剂的试验数据表明，这种治疗方法对所有患者都有重大益处。

覆盖区域

最近的三项试验之一评估了抗编程死亡配体1抗体atezolizumab与抗血管内皮生长因子单克隆抗体贝伐单抗的组合。在本手稿中，我们总结了阿特珠单抗治疗肾细胞癌的临床前，临床和安全性数据，并描述了正在进行的试验。

专家意见

评价阿特珠单抗与抗血管生成剂的组合。这些试验是基于以下假设而设计的：根据编程的死亡配体1的表达选择患者将增加治疗组合的益处。尽管对这些选定人群的主要终点无进展生存率和应答率产生积极影响，但总体人群的总体生存率仍未达到中间分析时的显着性标准。主要信息是拟议的肿瘤基因表达签名。该特征预示了对抗血管生成和/或免疫检查点抑制剂治疗的敏感性。